Inappropriate growth-hormone (GH) response to thyrotropin-releasing hormone (TRH) occurs infrequently in well-regulated diabetes mellitus

Acta diabetologica latina
O GiampietroR Navalesi

Abstract

We randomly administered thyrotropin-releasing hormone (200 micrograms, as an i.v. bolus) or control saline (in isovolumic amount) to 30 male diabetic subjects (23 IDDM, 7 NIDDM) in fair metabolic control (HbA1 9.7 +/- 0.3%, means +/- SEM) and to 12 healthy male controls on two different mornings. While GH in the basal state was similar in IDDM, NIDDM and normal subjects, TRH administration evoked a significant GH release only in a single IDDM individual. The only GH-responder to TRH was a newly-diagnosed (two weeks) IDDM patient, still with a high glycated hemoglobin level (HbA1 11.1%), despite normal plasma glucose levels. Saline infusion did not affect GH concentrations either in normals or in diabetics. Exaggerated GH responses to TRH are uncommon in diabetic patients in good metabolic conditions.

References

Jul 1, 1977·The Journal of Clinical Endocrinology and Metabolism·A E PaneraiE E Müller
Sep 1, 1977·The Journal of Clinical Endocrinology and Metabolism·A Zanoboni, W Zanoboni-Muciaccia
Mar 1, 1975·The Journal of Clinical Endocrinology and Metabolism·K MaedaH Imura
Sep 1, 1976·The Journal of Clinical Endocrinology and Metabolism·P CzernichowR Rappaport
Nov 1, 1987·Clinical Science·E C Griffiths
Dec 1, 1987·Metabolism: Clinical and Experimental·O GiampietroR Navalesi
Dec 1, 1987·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·O GiampietroE E Müller
Jan 1, 1988·Clinical Endocrinology·P G KopelmanJ P Monson
Sep 1, 1986·Metabolism: Clinical and Experimental·M W Stolar, G Baumann
Apr 24, 1971·British Medical Journal·B J OrmstonR Hall
Jan 1, 1973·The Journal of Clinical Endocrinology and Metabolism·D Gonzalez-BarcenaA V Schally
Jun 1, 1973·The Journal of Clinical Endocrinology and Metabolism·G FagliaA Spada
Nov 1, 1973·The Journal of Clinical Endocrinology and Metabolism·R B MimsJ E Bethune
Dec 2, 1971·The New England Journal of Medicine·M S AndersonA J Wise
Oct 1, 1971·Scandinavian Journal of Clinical and Laboratory Investigation·A P Hansen
Aug 1, 1970·The Journal of Clinical Investigation·A P Hansen
May 10, 1969·British Medical Journal·K Johansen, A P Hansen
Sep 1, 1984·Diabetic Medicine : a Journal of the British Diabetic Association·P S SharpE M Kohner
Jan 1, 1983·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·G SperoniG Valenti
Sep 1, 1983·The Journal of Clinical Endocrinology and Metabolism·E C DrobnyG Baumann
Mar 1, 1983·The Journal of Clinical Endocrinology and Metabolism·D Evain-BrionJ C Job
Oct 1, 1984·The Journal of Clinical Endocrinology and Metabolism·P ChioderaU Butturini
Dec 1, 1984·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·J KrassowskiS Zgliczyński
May 1, 1981·The Journal of Clinical Endocrinology and Metabolism·A DasmahapatraM P Cohen
Jan 21, 1982·The New England Journal of Medicine·I M Jackson
Jun 1, 1982·The Journal of Clinical Endocrinology and Metabolism·E RotiL E Braverman
May 1, 1980·Diabetes·J T HayfordR G Thompson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.